The visit is nearly over. The patient across from you is on a fourth antidepressant in under three years. The first did nothing. The second helped for a season, then quietly stopped. The third came off over side effects. The fourth is at week ten and the score has barely moved. You have four minutes and a decision about whether to say a word this person has almost certainly never heard.
Our survey of 443 Midwest adults says they have not. Asked about Spravato, 73 percent of respondents said they had no idea what we meant. Another 21 percent had bumped into it without learning what it meant, and 6 percent knew what it was. Plan the next sixty seconds as though you are the first person to say the word to them, because you probably are.
Why the sentence has to come from you
We also asked whose word would persuade them to try ketamine-type care. The answer from 74 percent was the doctor they already see. A friend or relative, the runner-up, moved just 18 percent. Ads got 2 percent, podcast hosts 1.
For a first stop, 56 percent chose the family doctor and 23 percent a psychiatrist. Twelve percent would search alone, and 5 percent would be lost for a place to begin.
Opening it when the word is brand new
The opening line has one job: give the patient permission to be unfamiliar, so they do not nod along and never follow up.
"I want to put something on your radar that most people have not heard of, so if this is new to you, that is normal. Given how these last few medications have gone, there is a category we have not tried, and I think it is worth you knowing it exists."
It matches how people search. Our 319 open-text answers about finding help were plain: "ptsd help," "therapist near me," "help with depression," and once, "someone please help me." Drug names never appeared.
Naming what it is, in one sentence
Patients keep one sentence from a rushed handoff, so put the logistics in it.
"It is esketamine, brand name Spravato. It is a spray, and its FDA approval is for depression that ordinary antidepressants have not lifted. Each dose happens in a certified office under observation, you wait there a while afterward, none of it goes home with you, and you stay on an antidepressant pill too."
"Isn't that a club drug?"
Concede the premise, then move to setting and oversight.
"Right molecule. Ketamine has been an anesthetic for decades and has also been misused. What changed is that one specific form passed FDA review for depression and is given on a schedule, in a controlled room, with a clinician watching. Same family, different context."
Skepticism is not rejection. In our poll, first reactions ran cautious but open at 34 percent and hopeful or curious at 18, against skeptical at 21 and negative at 9. FDA approval was decisive or a big factor for 59 percent, so regulatory standing answers the club drug question in the terms patients weigh.
Three different things with one nickname
- Esketamine, sold as Spravato, is the approved version for treatment-resistant depression: nasal spray, certified setting, supervised dosing, a monitoring period, no take-home supply, paired with an oral antidepressant.
- Generic IV ketamine for depression is off label, a regulatory fact rather than an accusation, and it changes what a payer does with the claim.
- At-home ketamine ordered through an online service is a third arrangement, without in-person monitoring. Say plainly that the three are not interchangeable, and that the cheapest, fastest search result is usually not what you described.
If a patient wants something to read after the visit, Brain Recovery Centers keeps a plain explanation of Spravato treatment that stays on the approved product.
Put coverage on the table before they ask
Insurance was a top-two provider consideration for 85 percent of respondents, far above closeness to home at 43 percent. It would decide or strongly shape whether 65 percent pursued treatment at all. Leave coverage unspoken and the patient hears an expensive idea meant for other people.
"Before you look this up and scare yourself on price, this is a covered benefit under many plans, with requirements. It usually means documenting the medications you have already tried and getting prior authorization. My office can find out what your plan wants. Do not let a number you saw online decide this."
Promise the check, never the outcome. Commercial plans, Medicare, MO HealthNet on the Missouri side, and TRICARE all handle this differently, and last year's rules are not this year's.
What to hand them
- Both words, esketamine and Spravato, spelled out, so the search at home reaches the right thing.
- Their medication history: agents, rough doses, duration, why each stopped. A treating clinician and a payer will both ask for it.
- Who you are referring to, or that you are finding out, and a date they will hear back. A patient who leaves without a next date leaves with a rumor.
- Your office number for the coverage question, so it does not become their research project.
When not to raise it
Skip the script when the medication history is not established, when adherence is the likelier explanation, when the diagnosis is still moving, or in the last ninety seconds of a heavy visit. A patient in acute crisis needs a different pathway. Deferring is a fine ending: "Let us book time for this alone."
Eligibility is a clinical judgment about one person's history, and it belongs to the clinician making it. Nothing here is clinical guidance. The survey describes how adults in this region decide where to seek care, not who should be treated with what.
One line belongs in the script wherever the referral lands. If a patient says the weight has turned into thoughts of not being here, tell them 988 works by phone or text, around the clock, for free, and connects straight to the Suicide and Crisis Lifeline. Say the number out loud. Patients in a fourth failed trial are the ones who stop believing help exists.
Methodology
Paid for and commissioned by this publisher, the survey sampled consumers, not physicians or a screened patient group. Pollfish collected 443 responses on its consumer panel from Midwest adults 18 to 64, spread over ten states, and stopped on June 23, 2026. Shares for multi-select items can total above 100. Pollfish has validated the panel, and these are its final numbers.